Ultimovacs As

Life Technologies As

Anne-Marie Rasmussen

Gustav Gaudernack

Else Marit Inderberg Suso

Gunnar Kvalheim

Tanja Aarvak

Walter Gabriell Borelli Piedras

Anne Brunsvig

A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.

Telomerase polypeptide vaccine for treating cancer

Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25&#x2212; T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.

Methods and materials for the generation of regulatory T cells

Growing community of inventors

Oslo, Norway

Anne-Marie Rasmussen